CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
First Claim
Patent Images
1. A humanized CD37-specific binding molecule, comprising from amino terminus to carboxyl terminus:
- (i) a humanized heavy chain variable region,(ii) a linker as set forth in SEQ ID NO;
229,(iii) a humanized light chain variable region,(iv) an IgG1 hinge,(v) a human IgG1 CH2 region, and(vi) a human IgG1 CH3 region,wherein(a) the humanized heavy chain variable region comprises from amino terminus to carboxyl terminus;
a human heavy chain FR1, a heavy chain CDR1 as set forth in SEQ ID NO;
63, a human heavy chain FR2, a heavy chain CDR2 as set forth in SEQ ID NO;
65, a human heavy chain FR3, a heavy chain CDR3 as set forth in SEQ ID NO;
67, 68 or 69, and a human heavy chain FR4, and(b) the humanized light chain variable region comprises from amino terminus to carboxyl terminus;
a human light chain FR1, a light chain CDR1 as set forth in SEQ ID NO;
61 or 62, a human light chain FR2, a light chain CDR2 as set forth in SEQ ID NO;
64, a human light chain FR3, and a light chain CDR3 as set forth in SEQ ID NO;
66, and a human light chain FR4.
5 Assignments
0 Petitions
Accused Products
Abstract
The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.
-
Citations
5 Claims
-
1. A humanized CD37-specific binding molecule, comprising from amino terminus to carboxyl terminus:
-
(i) a humanized heavy chain variable region, (ii) a linker as set forth in SEQ ID NO;
229,(iii) a humanized light chain variable region, (iv) an IgG1 hinge, (v) a human IgG1 CH2 region, and (vi) a human IgG1 CH3 region, wherein (a) the humanized heavy chain variable region comprises from amino terminus to carboxyl terminus;
a human heavy chain FR1, a heavy chain CDR1 as set forth in SEQ ID NO;
63, a human heavy chain FR2, a heavy chain CDR2 as set forth in SEQ ID NO;
65, a human heavy chain FR3, a heavy chain CDR3 as set forth in SEQ ID NO;
67, 68 or 69, and a human heavy chain FR4, and(b) the humanized light chain variable region comprises from amino terminus to carboxyl terminus;
a human light chain FR1, a light chain CDR1 as set forth in SEQ ID NO;
61 or 62, a human light chain FR2, a light chain CDR2 as set forth in SEQ ID NO;
64, a human light chain FR3, and a light chain CDR3 as set forth in SEQ ID NO;
66, and a human light chain FR4. - View Dependent Claims (2, 3, 4, 5)
-
Specification